RecruitingNCT06614595

Transfusion in Lower Risk MDS Patients: Predictors of Adequacy of Transfusion and Quality of Life in Lower Risk MDS

Transfusion in Lower Risk MDS Patients: Predictors of Adequacy of Transfusion and Quality of Life Changes

Sponsor

Fundación para la Investigación Biosanitaria del Principado de Asturias

Enrollment

30 participants

Start Date

Sep 20, 2024

Study Type

OBSERVATIONAL

Conditions

Low Risk Myelodysplastic Syndromes

Summary

Observational study to evaluate changes in quality of life (QoL) in patients diagnosed with low risk MDS who are red blood cell (abc) transfusion dependent. Changes in QoL will be correlated with patient cardiorespiratory function. Cardiac biomarkers and plasma cytokines will also be evaluated.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with low risk myelodysplastic syndromes. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Hospital Universitario Central de Asturias

Oviedo, Principality of Asturias, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06614595

Related Trials

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

NCT0530826415 locations

Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)

NCT066702223 locations